1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021

 
• By Cathy Kelly

Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.

Businessman hand stops domino continuous overturned meaning that hindered business failure. Stop over this business failure concept.
Payers Increasingly Seeking To Halt Use Of Manufacturer Coupons.

Nearly 50% of large US employers plan to implement copay accumulator programs in 2021 to block the impact of manufacturer-sponsored coupons, up from 39% using them in 2020, according to the Business Group on Health’s annual Health Care Strategy and Plan Design Survey, released 18 August.

Another 14% of employers said they are considering using copay accumulators during 2022-2023, the survey found. Fielded in May and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.